Join our daily newsletter At The Bell to receive exclusive market insights
Neurizon Therapeutics (ASX:NUZ) has dosed its first patient in the company’s amyotrophic lateral sclerosis (ALS) trial, with another 159 patients to come in a 36-week randomised double blind trial in the U.S.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with Neurizon Ltd and is intended for informational purposes only.
ALS, also called Lou Gehrig’s disease, is a neurodegenerative condition that affects the motor neurons that control muscle function – most importantly, movement – eventually leading to paralysis, and thereafter, respiratory failure.
NUZ-001, the drug that the trial will validate (all cards in order), has previously been reported as beneficial in a Phase I program that had a patient population of 12. The new trial of 160 patients is expected to wrap up in the second half of CY26.
Share price reaction was relatively positive on Thursday morning, with NUZ clocking a +3% gain out the gate, to sell at 10cps.
“The dosing of the first participant in Regimen I of the HEALEY ALS Platform Trial marks a defining milestone for Neurizon,” NUZ CEO Dr Michael Thurn said.
He added: “This study represents our registrational trial in ALS – a rigorous, adaptive Phase 2/3 program designed to generate the clinical evidence required to support potential regulatory submissions.”
The company wrote Thursday that its participation in the U.S.-based trial also affords NUZ access to leading ALS researchers and will give the company a closer proximity (literal and figurative) to the FDA.
NUZ last traded at 10cps today.
Join the discussion: See what HotCopper users are saying about Neurizon Therapeutics Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
